Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRE NASDAQ:IVA NASDAQ:KRRO NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$7.97+2.5%$7.61$6.57▼$11.78$773.30M2.0388,775 shs41,126 shsIVAInventiva$5.43+0.1%$5.80$2.85▼$7.98$791.78M0.7428,662 shs28,364 shsKRROKorro Bio$13.03+3.5%$12.36$5.20▼$55.89$187.82M3.07208,579 shs34,571 shsPURRHyperliquid Strategies$6.72+0.5%$5.42$3.01▼$6.88$837.42M1.444.56 million shs2.44 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-0.26%+1.43%+9.27%+0.13%-11.69%IVAInventiva+8.73%+8.18%-0.91%-8.91%+53.54%KRROKorro Bio-7.22%-1.64%-10.07%+2.69%-28.75%PURRHyperliquid Strategies+6.91%+13.42%+35.41%+670,299,900.00%+670,299,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$7.97+2.5%$7.61$6.57▼$11.78$773.30M2.0388,775 shs41,126 shsIVAInventiva$5.43+0.1%$5.80$2.85▼$7.98$791.78M0.7428,662 shs28,364 shsKRROKorro Bio$13.03+3.5%$12.36$5.20▼$55.89$187.82M3.07208,579 shs34,571 shsPURRHyperliquid Strategies$6.72+0.5%$5.42$3.01▼$6.88$837.42M1.444.56 million shs2.44 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-0.26%+1.43%+9.27%+0.13%-11.69%IVAInventiva+8.73%+8.18%-0.91%-8.91%+53.54%KRROKorro Bio-7.22%-1.64%-10.07%+2.69%-28.75%PURRHyperliquid Strategies+6.91%+13.42%+35.41%+670,299,900.00%+670,299,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 2.00Hold$17.00113.22% UpsideIVAInventiva 3.10Buy$16.56205.17% UpsideKRROKorro Bio 2.55Moderate Buy$37.29186.26% UpsidePURRHyperliquid Strategies 2.75Moderate Buy$8.1521.37% UpsideCurrent Analyst Ratings BreakdownLatest KRRO, GYRE, IVA, and PURR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026PURRHyperliquid Strategies Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.004/21/2026IVAInventiva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/8/2026KRROKorro Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/19/2026IVAInventiva Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.003/18/2026IVAInventiva Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/16/2026GYREGyre Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/13/2026KRROKorro Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $22.003/13/2026KRROKorro Bio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$23.003/2/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E)2/18/2026KRROKorro Bio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$18.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$116.59M6.63$0.22 per share35.64$1.48 per share5.39IVAInventiva$5.07M156.17N/AN/A($0.22) per share-24.66KRROKorro Bio$6.39M29.39N/AN/A$5.46 per share2.39PURRHyperliquid Strategies$1M832.46N/AN/A$1.52 per share4.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics$5.03M$0.01798.10N/AN/A4.31%10.85%9.16%5/7/2026 (Estimated)IVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/AN/AKRROKorro Bio-$117.26M-$12.47N/AN/AN/A-1,834.48%-115.95%-71.32%5/6/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$9.27N/A2.22N/AN/A-212.19%-199.12%N/ALatest KRRO, GYRE, IVA, and PURR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GYREGyre Therapeutics-$0.06N/AN/AN/A$31.61 millionN/A5/6/2026Q1 2026KRROKorro Bio-$1.7267N/AN/AN/A$0.76 millionN/A3/30/2026Q4 2025IVAInventiva-$0.18-$0.7480-$0.5680-$0.16$8.67 million$0.01 million3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 million3/12/2026Q4 2025KRROKorro Bio-$1.93-$5.32-$3.39-$5.32$0.43 million$1.29 million2/15/2026Q4 2025 TUIVAInventivaN/A-$0.16N/A-$0.16N/A$0.01 million2/11/2026Q2 2026PURRHyperliquid StrategiesN/A-$7.43N/A-$7.43N/A$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A5.605.04IVAInventivaN/A3.163.16KRROKorro BioN/A6.906.90PURRHyperliquid StrategiesN/A31.6231.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%IVAInventiva19.06%KRROKorro Bio13.18%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics10.00%IVAInventiva32.00%KRROKorro Bio4.60%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4096.99 million87.30 millionNo DataIVAInventiva100145.95 million99.25 millionNot OptionableKRROKorro Bio7014.42 million13.76 millionNo DataPURRHyperliquid StrategiesN/A123.97 million113.46 millionN/AKRRO, GYRE, IVA, and PURR HeadlinesRecent News About These CompaniesHyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026April 28, 2026 | prnewswire.comHyperliquid Strategies (NASDAQ:PURR) Trading Up 6.9% - Time to Buy?April 27, 2026 | marketbeat.comMaxim Group initiates coverage of Hyperliquid Strategies (PURR) with buy recommendationApril 26, 2026 | msn.comMaxim Group Begins Coverage on Hyperliquid Strategies (NASDAQ:PURR)April 24, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Gap Up - Here's WhyApril 22, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Down 7.7% - Time to Sell?April 21, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Gap Down - Should You Sell?April 20, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Reaches New 12-Month High - Still a Buy?April 14, 2026 | marketbeat.comHyperliquid Strategies Target of Unusually Large Options Trading (NASDAQ:PURR)April 13, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Gap Up After Analyst UpgradeApril 10, 2026 | marketbeat.comCantor Fitzgerald Upgrades Hyperliquid Strategies (NASDAQ:PURR) to Strong-BuyApril 10, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Down 8.4% - Should You Sell?April 7, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Up 7% - Time to Buy?April 6, 2026 | marketbeat.comHyperliquid Strategies Launches PURR Stock Options on Nasdaq to Expand Market AccessMarch 26, 2026 | crypto2community.comCHyperliquid Takes Over Wall Street: Can PURR Options Trigger a Fresh Rally?March 25, 2026 | newsbtc.comHyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common StockMarch 24, 2026 | prnewswire.comHigh Stakes Capital sells entire HYPE holdings in $22.9 million exitMarch 24, 2026 | msn.comHyperliquid DATs capture 7% of HYPE supply in push to replicate strategy's Bitcoin modelMarch 23, 2026 | msn.comHYPE Hits $42 as Hyperliquid Trading Activity SoarsMarch 18, 2026 | cryptonewsz.comCMicroStrategy Bleeds $1 Billion While This Firm Tops Every DAT in 2026 — What’s the SecretMarch 18, 2026 | beincrypto.comBAnalyst Says Hyperliquid Isn’t A Buy Right Now: Here’s WhyMarch 17, 2026 | newsbtc.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTop 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?By Thomas Hughes | April 6, 2026The Quiet Infrastructure Play on Small-Bank SurvivalBy Peter Frank | April 21, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 20263 Bargain-Cheap Small Caps Worth a Second LookBy Chris Markoch | April 9, 2026Joby’s Stock Just Got Its Wings Over New York CityBy Jeffrey Neal Johnson | April 28, 2026KRRO, GYRE, IVA, and PURR Company DescriptionsGyre Therapeutics NASDAQ:GYRE$7.97 +0.19 (+2.48%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Inventiva NASDAQ:IVA$5.42 +0.01 (+0.09%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Korro Bio NASDAQ:KRRO$13.02 +0.44 (+3.46%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Hyperliquid Strategies NASDAQ:PURR$6.72 +0.04 (+0.52%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
